Get started

Chart Patterns

BTC/USDT Analysis. Bitcoin is trading within an ascending channel but showing signs of weakness near $95,660. Here's the breakdown: $90,000–$92,500 remains critical for a potential bounce. A retest of this area could form a double bottom pattern. $97,500 (minor resistance) and $105,000 (upper channel boundary) are the key targets for any bullish continuation. A breakdown below $90,000 could lead BTC toward $85,000 or even $77,500 (major demand zone). Watch for price action near $90,000 for a possible reversal or continuation to lower levels. Volume and momentum indicators will be crucial to confirm the next move. DYOR, NFA @Peter_CSAdmin
Long
by CryptoSanders9563
Hellena | GOLD (4H): SHORT to the minimum of the “W” wave (2540)Dear colleagues, due to the recent sharp price movement I have redrawn the waves and at this point I can assume that we are dealing with a complex correction (W, X, Y). This means that I predict a price decline at least to the support area of 2540 - this is the area of the minimum of the “W” wave. It will most likely be followed by its renewal, but we will talk about it when the target is reached. Manage your capital correctly and competently! Only enter trades based on reliable patterns!
OANDA:XAUUSDShort
by Hellena_Trade
7
BTC enters the parabolic stage of the bullmarketPredicting the tops and bottoms of Bitcoin - in a macro sense - is not that easy. But some indicators can give us a clue or kind of sense of caution warning when to exit or enter the market. One of them is the "MVRV Z" indicator. It is a chart indicator that uses blockchain analysis to identify periods where BTC is extremely over or undervalued relative to its "fair value". Historically it has been very effective in identifying periods where market value is moving unusually high above realised value. It also shows when market value is far below realised value, highlighted by the green lines. Buying Bitcoin during these periods has historically produced outsized returns. This chart indicator is generally useful for predicting Bitcoin price at the extremes of market conditions. It is able to forecast where price may need to pull back when the score enters the upper red hot periods and also when price may rally after spending time in the lower green band. Historically it has picked major Bitcoin price highs to within 2 weeks. So far BTC has done a great job holding in the middle value band. It's in the stage of taking the next leap breaking out of it to the upside completing the bullmarket, also referring to past historical breakouts which happenend in similar fashion after a long lasting bearmarket.
INDEX:BTCUSDLong
by PizzaDriver
Trump Media & Technology Group (DJT): Big Moves Ahead?Good morning, trading family! Trump Media & Technology Group (DJT) is at a critical juncture, and here’s what we’re watching: If the price falls below $33.87: It could drop to $30-$28, with a chance of bouncing back to $59.57 afterward. If the price breaks above $38.51: We could see momentum push it to $59 or higher. If it fails to hold $28: Deeper declines may follow. These levels are key, and how the price reacts will set the direction. Let’s stay sharp and trade smart! Comment, like, follow, or send me a DM if you want more insights on this setup! Kris/Mindbloome Exchange Trade What You See
NASDAQ:DJT
by Mindbloome-Trading
#EURCAD 2HEURCAD (2H Timeframe) Analysis Market Structure: Channel Pattern: The price is moving within a defined channel, respecting both support and resistance levels. Currently, it is near the upper boundary of the channel, signaling potential resistance. Bearish Engulfing Area: A bearish engulfing candlestick pattern has appeared near the resistance zone, indicating possible selling pressure. Forecast: Sell Opportunity: The price is positioned at the channel resistance with bearish candlestick confirmation, suggesting a potential downward move within the channel. Key Levels to Watch: Entry Zone: Near the upper boundary of the channel or at the bearish engulfing area. Risk Management: Stop Loss: Placed above the channel resistance or engulfing candle high to protect against invalidation. Take Profit Zones: Target the midline or lower boundary of the channel as potential downside levels. Market Sentiment: Bearish Outlook: Sellers are likely to dominate as long as the price remains below the resistance area, maintaining a downward channel trend.
Short
by PIPSFIGHTER
Bullish Alert: DGB's Path to 300% Gains!DigiByte (DGB) recently saw its price surge dramatically. Now, it's testing a key price level that acts as support. Think of this support level as a safety net; if the price falls below it, the drop could be more significant. Successfully holding above this support would be a positive sign for the cryptocurrency. If DGB manages to maintain its position at this support level, we believe it could lead to another significant price rise, potentially up to 300% over the medium term. A successful retest would likely encourage more buying activity, pushing the price higher and creating a bullish trend for DGB.
by TheCryptoCity
Bullish tendency is broken 101-102K for sellingMorning folks, So, BTC was not able to stay above predefined support area and drop right back to the daily 92-95K level. It means that existing bullish context on daily chart is done. In general, this is reasonable - we're going to the Xmas Holidays and inauguration. There are a lot of uncertainty with coming D. Trump policy. Especially when JPowell said that the Fed doesn't intend to own any BTC... so inner conflict is ready. So, retracement might be deeper in nearest month. Since BTC is overextended down a bit, the first thing we expect upside technical bounce, somewhere to 101-102K area. Then, if we're correct in our analysis, downside reversal should happen with potential H&S pattern.
COINBASE:BTCUSDShort
by Sive-Morten
CHFJPY Trading Opportunity! SELL! My dear subscribers, CHFJPY looks like it will make a good move, and here are the details: The market is trading on 174.84 pivot level. Bias - Bearish My Stop Loss - 175.91 Technical Indicators: Both Super Trend & Pivot HL indicate a highly probable Bearish continuation. Target - 172.92 About Used Indicators: The average true range (ATR) plays an important role in 'Supertrend' as the indicator uses ATR to calculate its value. The ATR indicator signals the degree of price volatility. ——————————— WISH YOU ALL LUCK
Short
by AnabelSignals
1
BPTH could be in for a bull market in 2025!One new low cap stock pick with my research described below, please do your own research aswell and remember these are risky moves - thus small allocation. I will be back with many crypto charts for next year as well, don't worry! Bio-Path Holdings (BPTH) Overview: Bio-Path Holdings, Inc. is a biotechnology company focused on developing nucleic acid cancer drugs using its proprietary DNAbilize antisense RNAi nanoparticle technology. This technology allows for the development of drugs that can be administered through intravenous transfusion, targeting specific genes associated with cancer. Last week, Bio-Path Holdings announced preclinical results for their drug candidate BP1001-A. The study demonstrated that BP1001-A enhances insulin sensitivity, suggesting its potential as a treatment for obesity in patients with Type 2 diabetes. In 2025, Bio-Path Holdings plans to initiate a first-in-human Phase 1 clinical trial for BP1001-A, focusing on validating its safety, measuring pharmacokinetics, and establishing dosing for potential pivotal trials. This trial is aimed at further exploring BP1001-A's potential as a treatment for obesity and related metabolic diseases in patients with Type 2 diabetes. A successful trial would likely lead to a significant increase in Bio-Path Holdings' stock price. The news of positive clinical results would be seen as a validation of the drug's potential, attracting more investor interest and possibly leading to partnerships or buyouts from larger pharmaceutical companies. SPECULATION: Estimating the yearly revenue potential and a fair valuation for Bio-Path Holdings (BPTH) based on BP1001-A's market entry involves several speculative assumptions, as we lack specific data on market penetration, pricing, competition, and long-term efficacy. Here's a theoretical breakdown: Revenue Potential: Market Size and Share: Obesity and Type 2 Diabetes Market: The global market for treatments of obesity and Type 2 diabetes is substantial. For context, the global diabetes market alone was valued at approximately $51.1 billion in 2022, expected to reach $81.6 billion by 2030, growing at a CAGR of around 6.5% (). However, BP1001-A would be competing in a segment of this market focused on novel treatments or those with a unique mechanism like insulin sensitivity enhancement. Assumed Market Share: Assuming BP1001-A captures a niche segment, let's speculate it achieves a 1% to 5% market share due to its novel mode of action and targeting a specific subset of Type 2 diabetes patients with obesity. Pricing and Usage: Drug Pricing: New diabetes drugs, especially those with innovative mechanisms, can be priced high. For instance, if we assume a yearly cost per patient of $10,000 (considering the high cost of biologics and similar therapies), Patient Population: If we estimate that 1% of the diabetic population globally (approximately 537 million adults in 2021 according to IDF) could benefit from this drug, that's about 5.37 million patients. At 5% market share, this would mean 268,500 patients. Revenue Calculation: Annual Revenue: If 268,500 patients use BP1001-A at $10,000 per year, the potential annual revenue would be approximately $2.685 billion. For a 1% market share (53,700 patients), it would be around $537 million. Valuation: DCF Approach: A Discounted Cash Flow (DCF) analysis would be the traditional method to value BPTH if BP1001-A were to generate such revenues. Here's a simplified speculative approach: Cash Flow: Assuming 50% of revenue translates into gross profit (considering R&D, marketing, and other costs), a 1% market share would yield $268.5 million in gross profit, and 5% would yield $1.3425 billion. Discount Rate: Biotech companies often have high discount rates due to risk. Let's assume a 15% discount rate for this speculative valuation. Growth & Terminal Value: Assume growth stabilizes after initial high growth years, with a terminal growth rate of 2% post-patent exclusivity period (which might be around 20 years from patent to market). Valuation Calculation: With a 1% market share scenario: Present Value of Cash Flows for first 10 years (assuming rapid growth then stabilization): $268.5M * Annuity Factor at 15% = $1.4 billion (very roughly). Terminal Value (Gordon Growth Model) = $268.5M * (1+0.02)/(0.15-0.02) = $2.14 billion. Total Equity Value = PV of cash flows + Terminal Value = $3.54 billion. With a 5% market share scenario: Present Value of Cash Flows for first 10 years: $1.3425B * Annuity Factor at 15% = $7 billion (again, very roughly). Terminal Value = $1.3425B * (1+0.02)/(0.15-0.02) = $10.7 billion. Total Equity Value = $17.7 billion. Market Multiples: If we use industry multiples (PE ratios for biotech can be very high, especially for novel treatments), with a PE ratio of 20-30 for a company with significant growth potential, the valuation based on earnings from BP1001-A alone would range from: 1% Market Share: $5.37 billion (20 * $268.5M) to $8.055 billion (30 * $268.5M). 5% Market Share: $26.85 billion (20 * $1.3425B) to $40.275 billion (30 * $1.3425B). Fair Valuation: Given these speculative numbers, a fair valuation for BPTH based solely on BP1001-A's potential would be somewhere in the middle of these ranges, adjusted for the company's current financials, other pipeline drugs, and market conditions. Considering the above, a conservative estimate might place BPTH's valuation in the range of $3 billion to $10 billion, depending on market penetration optimism, with the understanding that this is highly speculative and subject to countless variables including regulatory approval, actual market acceptance, and competitive landscape. CONCLUSION & TA: This simply means, IF(!) this drug is succesfull the market cap of this company would significantly rise. Currently we're sitting at a 5.43 million market cap (at close, so lower now), thus its a 100 to 1000x potential or it drops to zero. Last note, price needs to stay above $1 to stay compliant with Nasdaq rules or else there could be an inverse stock split 2 to 1 for example or they face delisting by the end of Q3 2025. I'm not too worried because this is the same as SEALSQ faced before it 10x'd in the last few weeks. TA wise: we're retesting previous resistance and the bull market support band. Chart has been down only for years, capitulation after capitulation thus chance of a rebound should be there. I grabbed a small allocation to sit out for 2025, if the clinical trials are successful, we'll in for a big bull market. If not succesfull, we'll likely lose our money. A very decent risk / reward ratio of you invest an amount you can afford to lose and not more than 5% of your portfolio. This is one of my low cap stock picks, next to LAES (10x since entry) and MOBX (entry last week, flat pa for now). I will be scouting for more but for now, happy holidays!
NASDAQ:BPTHLong
by cryptobullethbtcxlm
APTUSDT Technical Analysis: Risk-Reward Setup with Dynamic Sp.LvRisk: %17 | Reward: %45 and beyond APTUSDT is exhibiting signs of potential price movement with significant technical indicators supporting the analysis. A noticeable bullish divergence on RSI and a temporary retracement towards a key support level may provide an ideal opportunity for long positions. Traders are advised to watch price action closely around the identified trendline and support zones for entry confirmations. Trading suggestion: A possible retracement to the $8.37 support line might occur. Traders can consider setting buy orders based on price action confirmation near the suggested support and aim for mid to long-term targets. Technical analysis: The RSI is oversold, indicating potential upside momentum if the trendline is respected. The DMF Index shows declining bearish pressure, hinting at a reversal possibility. SL = Break below $6.91 support zone. This setup offers a favorable risk-to-reward ratio with dynamic levels to monitor. Always trade with proper risk management strategies.
Long
by srmustafabas
Technical Analysis of Johnson & Johnson Stock (JNJ)This chart for JNJ illustrates a technical setup within a descending channel. Key Fibonacci retracement levels (38.2%, 50%, and 61.8%) are highlighted, indicating potential zones of support and resistance. The analysis suggests a three-part buying strategy: an initial purchase at the current market price (CMP) near a double-bottom structure, a second purchase around the $138–$136 range (61.8% Fibonacci level), and a third at the $133–$135 channel bottom. A stop loss is defined at $130 on a closing basis to manage downside risk, emphasizing disciplined trading within the defined channel boundaries.
NYSE:JNJLong
by jayshafiq2
Tesla - Breakout level re-test complete. Could launch from hereHello Traders. Looking at Tesla you can see many things that show Tesla is positioned to launch from here. 1.Previous times on the 2Hr since November when the 20/50 EMA crossed(DeathCross) Tesla went up shortly thereafter. It just crossed again. 2. Tesla recently broke out from ATH... but in the last few days came back down in a much needed cooling off and retested the breakout price and has bounced. This is MEGA bullish in my book. 3. You can clearly see an inverse Head & shoulder as well... 4. Bounced off the 2h 100EMA and Monthly VWAP. So without even showing other indicators ,which agree as well, You can clearly see Tesla is positioned for another mega bullish run. We could see 500+ by end of Christmas week.. and it heading even higher into the new year.
NASDAQ:TSLALong
by TheUniverse618